Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(3000.0%)
USD 1.24
(3000.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.94 Million GBP | -13.93% |
| 2022 | 3.42 Million GBP | 33615.87% |
| 2021 | 10.15 Thousand GBP | -99.38% |
| 2020 | 1.62 Million GBP | 29.5% |
| 2019 | 1.25 Million GBP | 7.2% |
| 2018 | 1.17 Million GBP | 0.0% |
| 2017 | - GBP | -100.0% |
| 2016 | 301.05 Thousand GBP | 24.62% |
| 2015 | 241.57 Thousand GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - GBP | -100.0% |
| 2024 Q2 | - GBP | 0.0% |
| 2023 Q4 | 2.94 Million GBP | 10.22% |
| 2023 Q2 | 3.26 Million GBP | 15.9% |
| 2023 Q1 | 2.81 Million GBP | -17.69% |
| 2023 Q3 | 2.67 Million GBP | -18.14% |
| 2023 FY | 2.94 Million GBP | -13.93% |
| 2022 Q1 | - GBP | -100.0% |
| 2022 Q2 | - GBP | 0.0% |
| 2022 Q4 | 3.42 Million GBP | 10.39% |
| 2022 FY | 3.42 Million GBP | 33615.87% |
| 2022 Q3 | 3.1 Million GBP | 0.0% |
| 2021 Q1 | 1.5 Million GBP | -7.6% |
| 2021 FY | 10.15 Thousand GBP | -99.38% |
| 2021 Q4 | 10.15 Thousand GBP | 0.0% |
| 2021 Q3 | - GBP | -100.0% |
| 2021 Q2 | 1.53 Million GBP | 1.95% |
| 2020 Q3 | 1.58 Million GBP | -9.34% |
| 2020 Q4 | 1.62 Million GBP | 2.44% |
| 2020 Q1 | 1.7 Million GBP | 35.82% |
| 2020 FY | 1.62 Million GBP | 29.5% |
| 2020 Q2 | 1.75 Million GBP | 2.67% |
| 2019 Q3 | 1.21 Million GBP | 3.43% |
| 2019 Q4 | 1.25 Million GBP | 3.28% |
| 2019 Q2 | 1.17 Million GBP | 0.0% |
| 2019 FY | 1.25 Million GBP | 7.2% |
| 2019 Q1 | 1.17 Million GBP | 0.35% |
| 2018 Q1 | - GBP | 0.0% |
| 2018 Q4 | 1.17 Million GBP | 0.0% |
| 2018 FY | 1.17 Million GBP | 0.0% |
| 2018 Q3 | 1.17 Million GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2017 Q1 | - GBP | -100.0% |
| 2017 FY | - GBP | -100.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2016 Q4 | 301.83 Thousand GBP | 0.0% |
| 2016 FY | 301.05 Thousand GBP | 24.62% |
| 2016 Q2 | - GBP | 0.0% |
| 2015 FY | 241.57 Thousand GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -53.033% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 92.85% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -633.083% |
| SQZ Biotechnologies Company | 27.47 Million USD | 89.276% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -26.653% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 93.208% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 90.104% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -210.659% |
| Marizyme, Inc. | 18.71 Million USD | 84.261% |
| Genus plc | 233.1 Million USD | 98.736% |
| Pharming Group N.V. | 171.54 Million USD | 98.283% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -231.72% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -119.256% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -292.785% |
| ContraFect Corporation | 2.88 Million USD | -2.252% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -103.682% |
| IMV Inc. | 28.88 Million USD | 89.801% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 47.937% |
| ONE Bio Corp. | 19.71 Million USD | 85.058% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 94.876% |
| Mesoblast Limited | 118.7 Million USD | 97.518% |
| MultiCell Technologies, Inc. | 202.58 USD | -1454084.026% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 91.1% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.295% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -367.544% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -139.822% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 28.532% |
| Biomind Labs Inc. | 735.54 Thousand USD | -300.505% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 2.654% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 77.334% |
| Skye Bioscience, Inc. | 4.61 Million USD | 36.171% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -718.961% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -0.529% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1981.633% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2074.294% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 49.824% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -11354.123% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -97.082% |
| Q BioMed Inc. | 4.1 Million USD | 28.324% |
| GB Sciences, Inc. | 1.75 Million USD | -67.446% |
| Alpha Cognition Inc. | 1.22 Million USD | -141.392% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Agentix Corp. | 50 Thousand USD | -5791.772% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.645% |
| Enzolytics Inc. | 996.33 Thousand USD | -195.671% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 54.616% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1052.574% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -30.442% |
| argenx SE | 20 Million USD | 85.271% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 93.534% |
| HST Global, Inc. | 98.31 Thousand USD | -2896.253% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1084.419% |
| Halberd Corporation | 150 Thousand USD | -1863.924% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 58.349% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -28710.621% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -8.756% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -22.862% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1184.78% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1881.707% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1368.42% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -33.911% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 85.508% |
| Kadimastem Ltd | 891.22 Thousand USD | -230.543% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 37.473% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1077.497% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -8665.953% |
| Cell Source, Inc. | 9.25 Million USD | 68.167% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -289.562% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -289.562% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -508.297% |
| Itoco Inc. | 228.37 Thousand USD | -1189.922% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1296.32% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 40.881% |
| International Stem Cell Corporation | 4.17 Million USD | 29.491% |
| CytoDyn Inc. | 30.07 Million USD | 90.205% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -737.263% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 62.329% |
| SYBLEU INC | 477.5 Thousand USD | -516.939% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2304.805% |
| Rebus Holdings, Inc. | 310 Thousand USD | -850.286% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 37.789% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4619.988% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -35.077% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 64.576% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 65.686% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -89.388% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -999.211% |
| Neutra Corp. | 54.15 Thousand USD | -5339.63% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -60.977% |
| PureTech Health plc | 25.51 Million USD | 88.453% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -140.633% |
| IXICO plc | 472.02 Thousand USD | -524.098% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 80.996% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 95.269% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Cellectis S.A. | 92.77 Million USD | 96.825% |